» Authors » Nazzareno Cannella

Nazzareno Cannella

Explore the profile of Nazzareno Cannella including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 57
Citations 848
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhuang S, Shi F, Cannella N, Ubaldi M, Ciccocioppo R, Li H, et al.
Antioxidants (Basel) . 2025 Feb; 14(2). PMID: 40002422
This review explores the antidepressant effects of ginsenoside Rb1, a natural compound in traditional Chinese medicine, and its potential for treating major depressive disorder (MDD). The aetiology of depression was...
2.
Kuhn B, Cannella N, Chitre A, Nguyen K, Cohen K, Chen D, et al.
Mol Psychiatry . 2025 Feb; PMID: 40000848
The increased prevalence of opioid use disorder (OUD) makes it imperative to disentangle the biological mechanisms contributing to individual differences in OUD vulnerability. OUD shows strong heritability, however genetic variants...
3.
Kuhn B, Cannella N, Crow A, Lunerti V, Gupta A, Walterhouse S, et al.
Am J Psychiatry . 2025 Jan; 182(2):198-208. PMID: 39810557
Objective: The behavioral and diagnostic heterogeneity within the opioid use disorder (OUD) diagnosis is not readily captured in current animal models, limiting the translational relevance of the mechanistic research that...
4.
Curti L, Rizzi B, Mottarlini F, Bigagli E, Ilari A, Costa A, et al.
Prog Neuropsychopharmacol Biol Psychiatry . 2024 Oct; 136():111174. PMID: 39447689
Background: Prenatal alcohol exposure (PAE) induces a wide range of neurodevelopmental disabilities that are grouped under the term 'fetal alcohol spectrum disorders' (FASD). The effects of PAE on brain development...
5.
Kuhn B, Cannella N, Crow A, Lunerti V, Gupta A, Walterhouse S, et al.
bioRxiv . 2024 Aug; PMID: 39211180
Objective: The behavioral and diagnostic heterogeneity within human opioid use disorder (OUD) diagnosis is not readily captured in current animal models, limiting translational relevance of the mechanistic research that is...
6.
Cannella N, Lunerti V, Shen Q, Li H, Benvenuti F, Soverchia L, et al.
Neuropharmacology . 2024 Jun; 257:110048. PMID: 38901642
Maintenance therapy with buprenorphine and methadone is the gold standard pharmacological treatment for opioid use disorder (OUD). Despite these compounds demonstrating substantial efficacy, a significant number of patients do not...
7.
Greenberg J, Winters A, Zagorac B, Kracht D, Francescutti D, Cannella N, et al.
Front Psychiatry . 2024 Mar; 15:1369783. PMID: 38476614
Introduction: It is well known that chronic opioid use disorder is associated with alterations in gastrointestinal (GI) function that include constipation, reduced motility, and increased bacterial translocation due to compromised...
8.
Cannella N, Tambalo S, Lunerti V, Scuppa G, de Vivo L, Abdulmalek S, et al.
bioRxiv . 2024 Mar; PMID: 38463974
In opioid use disorder (OUD) patients, a decrease in brain grey matter volume (GMV) has been reported. It is unclear whether this is the consequence of prolonged exposure to opioids...
9.
Cannella N, Tambalo S, Lunerti V, Scuppa G, de Vivo L, Abdulmalek S, et al.
Brain Behav Immun . 2024 Mar; 118:210-220. PMID: 38452987
In opioid use disorder (OUD) patients, a decrease in brain grey matter volume (GMV) has been reported. It is unclear whether this is the consequence of prolonged exposure to opioids...
10.
Lunerti V, Shen Q, Li H, Benvenuti F, Soverchia L, Narendran R, et al.
bioRxiv . 2023 Aug; PMID: 37546836
The gold standard pharmacological treatment for opioid use disorder (OUD) consists of maintenance therapy with long-acting opioid agonists such as buprenorphine and methadone. Despite these compounds having demonstrated substantial efficacy,...